{"id":316,"date":"2019-05-20T11:49:47","date_gmt":"2019-05-20T11:49:47","guid":{"rendered":"https:\/\/www.bensnaturalhealth.com\/blog\/?p=316"},"modified":"2026-08-05T09:32:27","modified_gmt":"2026-08-05T09:32:27","slug":"prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.bensnaturalhealth.com\/blog\/prostate-health\/prostate-cancer\/","title":{"rendered":"Prostate Cancer: Causes, Symptoms, Treatments"},"content":{"rendered":"Prostate cancer is the most common cancer diagnosis in American men, and in 2026,<\/span> roughly 333,830 new cases<\/span><\/a> are expected in the U.S. alone. The good news is that when it’s caught early, it’s among the most treatable cancers a man can face. This article walks you through what prostate cancer is, what to watch for, how it’s diagnosed, and what treatment looks like from first conversation to long-term follow-up.<\/span>\n

What Is Prostate Cancer and Who Gets It<\/b><\/h2>\nProstate cancer begins when cells in the prostate gland – the walnut-sized gland below the bladder that helps produce semen – start multiplying without normal controls. In most cases, these abnormal cells grow slowly. But certain forms are aggressive and can invade nearby tissue, lymph nodes, or bone if they go untreated.<\/span>\n

How Common Is Prostate Cancer<\/b><\/h3>\nIt’s very common. According to<\/span> a 2025 report from the American Cancer Society<\/span><\/a>, prostate cancer accounts for roughly 30% of all new male cancer diagnoses. A<\/span> 2026 global overview<\/span><\/a> puts worldwide prevalence at over 5 million men. Incidence rates, which declined through the early 2010s, have since reversed. A<\/span> 2025 analysis in CA: A Cancer Journal for Clinicians<\/span><\/a> found incidence rising 3.0% annually since 2014, with the steepest increases in advanced-stage diagnoses. Per<\/span> Dr. Catalona’s 2026 statistics page<\/span><\/a>, the 5-year relative survival rate for localized prostate cancer exceeds 99%.<\/span>\n

What Happens When Cancer Develops in the Prostate<\/b><\/h3>\nHealthy prostate cells follow a predictable schedule: they grow, divide, and die in an orderly way. Cancer begins when DNA damage breaks that cycle, typically in the glandular cells lining the prostate. The altered cells keep multiplying, building into a tumor. That tumor can eventually breach the prostate’s surrounding capsule and, in advanced cases, travel through the lymphatic system or bloodstream to distant parts of the body.<\/span>\n

Risk Factors and Causes of Prostate Cancer<\/b><\/h2>\nNo single cause accounts for every prostate cancer diagnosis. But several<\/span> well-documented risk factors<\/span><\/a> can significantly raise a man’s odds. The<\/span> American Cancer Society’s risk factor summary<\/span><\/a> divides these into factors you can’t change and those you actually can.<\/span>\n

Age, Race, and Family History<\/b><\/h3>\nAge is the single biggest risk factor. Most diagnoses occur in men over 50, and risk accelerates after 65. Race matters too,<\/span> a CDC WONDER database analysis<\/span><\/a> confirmed that non-Hispanic Black men bear a disproportionately high mortality burden, with double the death rate of non-Hispanic White men despite receiving similar diagnoses.<\/span>\n\nFamily history raises risk significantly. Having a father or brother with prostate cancer roughly doubles your personal risk. Genetic predisposition runs deeper than family history alone. A 2025 study published in <\/span>European Urology Oncology<\/span><\/i> found that<\/span> heritable factors account for 57% of risk<\/span><\/a> variability overall. Polygenic risk scores built from over 400 identified variants can now explain 40 to 50% of familial incidence. If two or more genetic risk factors cluster together (family history, a high polygenic risk score, and rare DNA-repair gene variants), the odds of early lethal disease increase roughly threefold,<\/span> per Latin America mortality predictions research<\/span><\/a> that cross-validated similar genetic architectures.<\/span>\n\nDetailed coverage of<\/span> what causes prostate cancer<\/span><\/a> at the cellular level is available if you want more depth on the DNA-change mechanisms involved.<\/span>\n

Lifestyle Factors and Other Risks<\/b><\/h3>\nDiet and body weight play a real role. Obesity is linked to a higher risk of aggressive prostate cancer and poorer outcomes after treatment.<\/span> Losing weight can meaningfully lower prostate cancer risk<\/span><\/a>, and keeping a healthy BMI is one of the few controllable levers men have. A diet heavy in processed red meat and short on vegetables may also raise risk, though the evidence on that remains mixed. Adequate vitamin D levels may also matter,<\/span> vitamin D and cancer risk<\/span><\/a> is an active area of research, with some evidence suggesting deficiency correlates with more aggressive disease.<\/span>\n\nSmoking is tied to more aggressive prostate cancer<\/span><\/a> across multiple studies. Quitting is one of the clearest things you can do for your overall health. Preventive steps – eating more plant foods, staying physically active, maintaining a healthy weight – won’t guarantee you avoid the disease, but they do shift the odds in a better direction.<\/span>\n

Early Signs and Symptoms to Watch For<\/b><\/h2>\nEarly prostate cancer often has no symptoms at all. That’s why screening matters. When symptoms do appear, they tend to reflect how the tumor is pressing on or affecting nearby structures.<\/span>\n

Urinary and Bowel Changes<\/b><\/h3>\nBecause the prostate sits directly below the bladder and wraps around the urethra, urinary changes are often the first signal something’s wrong. According to<\/span> a 2025 epidemiology review from MDPI<\/span><\/a>, the most frequently reported early urinary symptoms include a weak or interrupted urine stream, difficulty getting urination started, frequent nighttime urination (called nocturia), and a persistent sense that the bladder hasn’t fully emptied. Blood in the urine (hematuria) is less common but needs immediate attention. Bowel changes – including pain during bowel movements – can develop when a tumor grows toward the rectum, and men who notice new lower bowel symptoms should also be aware that<\/span> bladder cancer screening and diagnosis<\/span><\/a> covers a distinct but sometimes overlapping set of urinary red flags worth understanding.<\/span>\n

Sexual Dysfunction and Pain<\/b><\/h3>\nErectile dysfunction and painful ejaculation can both be associated with prostate cancer, though they’re also common with other conditions. Men who develop<\/span> erectile dysfunction as a treatment side effect<\/span><\/a> should know that a range of causes, diagnostic steps, and therapies exist beyond what prostate treatment alone addresses. Blood in semen, or hematospermia, is a red flag that should always be evaluated by a doctor. Pelvic discomfort or pain in the lower back, hips, or thighs may reflect local invasion. Pain in these areas,<\/span> as the 2025 ACS data confirms<\/span><\/a>, can also signal bone metastasis in advanced disease. Bone pain (particularly in the spine, pelvis, or ribs) is a specific red flag for metastatic spread and should never be dismissed.<\/span>\n

When Symptoms Warrant a Doctor’s Visit<\/b><\/h3>\nAny new urinary symptoms lasting more than a week or two deserve a conversation with your doctor. Don’t wait on blood in the urine or semen, persistent pelvic pain, or bone pain. These symptoms don’t confirm cancer – they can have other explanations – but they’re your body signaling that something needs to be checked.<\/span>\n

How Prostate Cancer Is Diagnosed<\/b><\/h2>\nProstate cancer diagnosis involves two separate phases: screening (finding men who may be at risk) and diagnostic testing (confirming whether cancer is actually present). These are different things, and understanding that distinction matters.<\/span>\n

PSA Blood Tests and Digital Rectal Exams<\/b><\/h3>\nThe prostate-specific antigen (PSA) test is the primary screening tool. It measures PSA levels in a blood sample; elevated values can suggest cancer, though they can also reflect an enlarged prostate or infection.<\/span> Routine screening tests for men<\/span><\/a> generally include PSA testing as part of annual checkups for men 50 and older, or 45 for those at higher risk, such as Black men or those with a first-degree relative who had prostate cancer. The USPSTF recommends that men aged 55 to 69 make individual decisions about PSA screening after talking through the benefits and risks with their doctor; it advises against routine screening in men 70 and older.<\/span>\n\nA digital rectal exam (DRE) lets a doctor physically feel the prostate through the rectal wall. About 18% of prostate cancers are detected through a suspicious DRE result alone, regardless of PSA level. The<\/span> 4K score blood test<\/span><\/a> combines four PSA-related markers to better estimate the risk of aggressive cancer, helping some men avoid unnecessary biopsies.<\/span>\n

Biopsy and Imaging to Confirm Diagnosis<\/b><\/h3>\nAn elevated PSA or abnormal DRE triggers further investigation.<\/span> Multiparametric MRI for prostate cancer<\/span><\/a> can spot suspicious lesions before biopsy, sharpening the accuracy of targeted sampling.<\/span> Transrectal ultrasound (TRUS) guided biopsy<\/span><\/a> is still the most widely used diagnostic procedure;<\/span> prostate ultrasound<\/span><\/a> helps guide needle placement during the procedure. Tissue samples are then examined under a microscope for cancer cells.<\/span>\n\nIncreasingly, genetic and biomarker testing plays a role in diagnosis and treatment decisions. A 2025 study in <\/span>European Urology Oncology<\/span><\/i> found that polygenic risk scoring built from<\/span> over 400 identified genetic variants<\/span><\/a> can identify men at elevated risk for early lethal disease, enabling more targeted surveillance in high-risk groups.<\/span>\n

Stages and Grading: What Your Diagnosis Means<\/b><\/h2>\nOnce cancer is confirmed, staging and grading tell your care team how aggressive it is and how far it has spread.<\/span>\n

Understanding Gleason Scores and Staging<\/b><\/h3>\nThe<\/span> Gleason score<\/span><\/a> grades cancer cells by how abnormal they look compared to normal prostate tissue. A pathologist assigns a grade of 1 to 5 to the two most prevalent cell patterns found in the biopsy, then adds those numbers together. Scores run from 6 (low-grade, slow-growing) to 10 (high-grade, aggressive). A Gleason score of 7 can carry different implications depending on the pattern: 3+4 is generally considered less aggressive than 4+3.<\/span>\n\nStaging follows the TNM system: Tumor size (T), lymph Node involvement (N), and Metastasis (M). Stage I and II cancers are still confined to the prostate. Stage III, covered in detail in<\/span> stage 3 prostate cancer<\/span><\/a>, has spread into nearby tissue. Stage IV has reached distant organs or bone.<\/span>\n

Risk Categories and Prognosis<\/b><\/h3>\n\n\n\n\n\n\n\n
Risk Group<\/b><\/td>\nPSA Level<\/b><\/td>\nGleason Score<\/b><\/td>\n5-Year Survival<\/b><\/td>\n<\/tr>\n
Low<\/span><\/td>\n< 10 ng\/mL<\/span><\/td>\n\u2264 6<\/span><\/td>\n>99%<\/span><\/td>\n<\/tr>\n
Intermediate<\/span><\/td>\n10 to 20 ng\/mL<\/span><\/td>\n7<\/span><\/td>\n>99%<\/span><\/td>\n<\/tr>\n
High<\/span><\/td>\n> 20 ng\/mL<\/span><\/td>\n8 to 10<\/span><\/td>\n>99% (localized)<\/span><\/td>\n<\/tr>\n
Metastatic<\/span><\/td>\nAny<\/span><\/td>\nAny<\/span><\/td>\n~32%<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\nThe 5-year survival rate for localized prostate cancer exceeds 99%, while metastatic disease carries a much lower rate. A<\/span> 2025 BMC analysis<\/span><\/a> projects global prostate cancer cases will nearly double from 1.4 million in 2020 to 2.9 million by 2040, underlining why accurate staging matters at a population level. The<\/span> connection between diabetes and cancer<\/span><\/a> is also relevant here, as metabolic disease can influence both cancer progression and treatment tolerance.<\/span>\n

Treatment Options for Prostate Cancer<\/b><\/h2>\nA<\/span> 2025 PubMed review<\/span><\/a> of treatment approaches confirms that the right option depends heavily on stage, grade, age, and overall health. There’s no single answer for every man.<\/span>\n

Active Surveillance and Watchful Waiting<\/b><\/h3>\nActive surveillance suits low-risk, slow-growing cancers well. It means regular PSA tests at least every 6 months, annual digital rectal exams, and periodic repeat biopsies. Men stay on surveillance as long as the cancer shows no signs of progression, in many low-risk cases, that can stretch years or even decades. This isn’t inaction; it’s a monitored strategy that protects against overtreatment. Watchful waiting is a less intensive version, typically reserved for older men or those with serious health conditions where treatment side effects would outweigh any benefit.<\/span>\n

Surgery and Radiation Therapy<\/b><\/h3>\nA prostatectomy surgically removes the prostate gland, either through open surgery or – increasingly – robot-assisted laparoscopic techniques. The aim is eliminating the cancer before it spreads. Radiation therapy directs focused beams (external beam radiation) or implanted radioactive seeds (brachytherapy) at cancer cells to destroy them. Both approaches achieve comparable survival outcomes in localized disease, but their side-effect profiles differ, especially around urinary and sexual function. Focal therapies like high-intensity focused ultrasound (HIFU) are emerging as options for carefully selected patients.<\/span>\n

Hormone Therapy and Chemotherapy<\/b><\/h3>\nHormone therapy – also called androgen deprivation therapy, or ADT – lowers the body’s testosterone levels because prostate cancer cells typically depend on testosterone to grow. Blocking testosterone slows tumor growth and can shrink metastatic disease, and men considering this path should understand that testosterone and male health more broadly – including muscle mass, bone density, and mood – are all affected by prolonged androgen suppression, which<\/span> working out can help partially offset<\/span><\/a>. It’s often paired with radiation for high-risk localized cancer, or used as the backbone of treatment for advanced disease. PARP inhibitors, including olaparib and rucaparib, are now FDA-approved for men with metastatic castration-resistant prostate cancer (mCRPC) who carry BRCA or other DNA-repair gene mutations. Radioligand therapy (177Lu-PSMA-617) in the VISION trial extended overall survival from a median of 11.3 months to 15.3 months in mCRPC patients. Chemotherapy – primarily docetaxel – comes in when cancer stops responding to hormone therapy. Immunotherapy remains limited in prostate cancer; it tends to be an immunologically “cold” tumor, though CAR-T and bispecific antibody approaches are under active investigation.<\/span>\n

Side Effects and What to Expect During Treatment<\/b><\/h2>\nTreatment side effects vary significantly depending on the approach, and knowing what to expect helps you prepare and manage them proactively.<\/span> A detailed guide to managing prostate cancer treatment side effects<\/span><\/a> covers coping strategies in depth.<\/span>\n

Urinary, Bowel, and Sexual Side Effects<\/b><\/h3>\nSurgery commonly causes temporary<\/span> urinary incontinence<\/span><\/a> and erectile dysfunction. Most men regain urinary control within months, though full recovery can take up to a year. Radiation is more likely to affect bowel function, producing urgency or rectal irritation, and carries its own risk of urinary changes. Hormone therapy reduces libido and sexual function, causes hot flashes, and can reduce muscle mass and bone density over time. A<\/span> 2025 PMC genetics study<\/span><\/a> notes that genetic factors can influence how men respond to the hormonal shifts that treatment causes. Pain or burning during urination or ejaculation can sometimes reflect treatment effects rather than the cancer itself, worth clarifying with your care team. Men recovering from treatment who experience persistent sexual dysfunction may benefit from<\/span> exercises to help erectile dysfunction after treatment<\/span><\/a>, which can support pelvic floor recovery alongside other rehabilitation strategies.<\/span>\n

Managing Fatigue and Other Treatment Effects<\/b><\/h3>\nFatigue is the most commonly reported side effect across all treatment types. Chemotherapy also brings nausea, hair loss, and greater infection risk. Men on hormone therapy may notice mood changes, lower energy, and cognitive shifts. For men on active surveillance, the timeline before any escalation varies – some stay on monitoring for 10 or more years without needing intervention. Exercise, dietary support, and open communication with your care team are practical ways to manage side effects throughout. Men undergoing treatment may also find that targeted natural supplements, used alongside medical care and discussed with their doctor first, can support areas like urinary function and hormonal balance – but they’re not a substitute for prescribed treatment.<\/span>\n

Life After Prostate Cancer Treatment<\/b><\/h2>\nRecovery doesn’t end on the day treatment finishes. Follow-up care is ongoing, and for good reason.<\/span>\n

Follow-Up Care and Monitoring<\/b><\/h3>\nMost men have PSA tests every 3 to 6 months for the first 2 years after treatment, then annually if levels stay stable. A rising PSA after surgery – called a biochemical recurrence – signals that cancer cells may still be active somewhere in the body, even when imaging shows nothing yet. Men who move from active surveillance into treatment also continue PSA monitoring post-treatment. For those whose cancer recurs or progresses, several medication-based options exist: second-generation hormone therapies like enzalutamide and abiraterone, PARP inhibitors for BRCA-mutated disease, and in some cases, radioligand therapy.<\/span>\n

Recurrence Risk and Long-Term Outlook<\/b><\/h3>\nProstate cancer recurrence<\/span><\/a> is the primary driver of cancer mortality in men with the disease. Recurrence rates after radical prostatectomy range from 20 to 40% over 10 years, depending on pathological stage and Gleason score. High-risk and node-positive cancers carry a meaningfully higher recurrence probability than low-risk localized disease. Research on<\/span> the complex genetic epidemiology of prostate cancer<\/span><\/a> shows that heritable factors shaping disease aggressiveness remain relevant even after initial treatment, particularly in men with BRCA2 mutations. The long-term outlook for localized disease is excellent; for metastatic disease, ongoing treatment can extend survival significantly.<\/span>\n

When to Seek Medical Help and Red Flags<\/b><\/h2>\nSome symptoms are urgent. Don’t wait for your next routine appointment if you notice any of the following:<\/span>\n